Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib

Alumis (NASDAQ:ALMS), which develops targeted therapies for immune-mediated diseases, closed Tuesday’s session at $16.23, up 95.31%. Trading volume reached 64.1 million shares, coming in about 3,077% above its three-month average of 2 million shares.Tuesday's move followed Phase 3 psoriasis data for envudeucitinib, which investors are treating as a potential commercial inflection point. The focus is now watching New Drug Application (NDA) timing and competitive dynamics in oral TYK2 inhibitors. The S&P 500 (SNPINDEX:^GSPC) rose 0.62% to 6,945, while the Nasdaq Composite (NASDAQINDEX:^IXIC) gained 0.65% to finish at 23,547. Biotechnology peers Summit Therapeutics (NASDAQ:SMMT) and Insmed (NASDAQ:INSM) saw mixed moves, underscoring how stock-specific trial readouts are driving sentiment across the biotechnology group.Alumis is a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases. Today's positive Phase 3 results achieved both primary and secondary endpoints with strong statistical significance in individuals with moderate-to-severe plaque psoriasis.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool